Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds [Seeking Alpha]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Seeking Alpha
Recent FDA draft guidance allowing MRD negativity as a surrogate endpoint significantly de-risks and accelerates Carvykti's path to broader approvals. LEGN's robust cash position (~$1B) and improving financials provide an 8.5-year runway, supporting ongoing R&D and commercialization efforts. At a 3.58x EV/sales multiple, LEGN trades at a discount to pre-revenue peers, with Carvykti's global commercialization underpinning a compelling risk-reward profile. Miyako Nakamura/E+ via Getty Images Thesis Legend Biotech ( LEGN ) is set to present six new poster analyses on Carvykti at the 2026 Tandem Meetings. It should take place from February 4th to the 7th in Salt Lake. I expect This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compens
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San FranciscoPR Newswire
- Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Legend Biotech (NASDAQ:LEGN) was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..MarketBeat
- Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.MarketBeat
LEGN
Sec Filings
- 1/23/26 - Form 6-K
- 1/21/26 - Form 6-K
- 1/14/26 - Form 6-K
- LEGN's page on the SEC website